Source-grounded facts extracted from Aquestive Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Aquestive Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm at the 2026-06-10 meeting.
“The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified. Votes For Votes Against Votes Abstaining 78,804,323 910,690 346,313”
Aquestive Therapeutics, Inc. shareholders approved Advisory vote to approve executive compensation at the 2026-06-10 meeting.
“The proposal to approve, on a non-binding advisory basis, executive compensation was approved for the one year. Votes For Votes Against Votes Abstaining Broker Non-Votes 37,798,609 3,192,381 1,604,754 37,465,582”
Aquestive Therapeutics, Inc. shareholders approved Election of Class II directors at the 2026-06-10 meeting.
“The following director nominees were elected to serve as Class II members of the Board of Directors, to serve for a three-year term until the Company's 2029 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Nominee Votes For Votes Against Votes Abstaining Broker Non-Votes Gregory B. Brown, M.D. 41,373,033 — 1,222,711 37,465,582 John S. Cochran 36,914,899 — 5,680,845 Abigail L. Jenkins 39,094,166 — 3,501,578”
Aquestive Therapeutics, Inc. entered into Credit Agreement with Oaktree Fund Administration, LLC, as administrative agent, and certain funds managed by Oaktree Capital Management, L.P. valued at term loan facility of up to $150.0 million (effective 2026-05-12).
“On May 12, 2026 (the “Effective Date”), Aquestive Therapeutics, Inc. (the “Company”) entered into a five-year term loan facility of up to $150.0 million (the “Term Loan”)”
Aquestive Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 13, 2026, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the first quarter ended March 31, 2026 and provided an update on recent developments in its business.”
Aquestive Therapeutics, Inc. incurred credit facility of up to $150.0 million with Oaktree Fund Administration, LLC, as administrative agent, and certain funds managed by Oaktree Capital Management, L.P. as Lenders at three-month SOFR (with a floor of 2.75%) plus 6.25% maturing five years from the closing date.
“On May 12, 2026 (the “Effective Date”), Aquestive Therapeutics, Inc. (the “Company”) entered into a five-year term loan facility of up to $150.0 million (the “Term Loan”), consisting of a term loan in an aggregate principal amount of $55.0 million that was funded on the Effective Date (the “Tranche A Term Loan”), a term loan in an aggregate principal amount of $20.0 million available subject to certain terms and conditions (the “Tranche B Term Loan”), a term loan in an aggregate principal amount of $25.0 million available subject to certain terms and conditions (the “Tranche C Term Loan”), and a term loan advance available upon the mutual consent of the Lenders and subject to certain terms and conditions in an aggregate principal amount of up to $50.0 million (the “Tranche D Term Loan”), pursuant to a credit agreement and guaranty, dated as of the Effective Date (the “Credit Agreement”), with Oaktree Fund Administration, LLC, a Delaware limited liability company, as administrative agen”
Aquestive Therapeutics, Inc. reported financial results for the quarter and fiscal year ended December 31, 2025.
“On March 4, 2026, Aquestive Therapeutics, Inc. issued a press release announcing its reported financial results for the quarter and fiscal year ended December 31, 2025 and providing an update on recent developments in its business.”
Aquestive Therapeutics, Inc. issued up to 375,000 shares of warrant to funds managed by RTW Investments, LP for exercise price of $4.00 per share.
“the Company entered into a Warrant Issuance Agreement with funds managed by RTW pursuant to which the Company agreed to issue a warrant to purchase up to 375,000 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $4.00 per share, expiring on March 3, 2029.”
Aquestive Therapeutics, Inc. entered into Share Purchase Commitment Agreement with certain RTW-affiliated funds valued at not less than $5,000,000 (effective 2026-03-03).
“The Company also entered into a Share Purchase Commitment Agreement with certain RTW-affiliated funds, pursuant to which such funds committed to purchase, in the aggregate, not less than $5,000,000 of Common Stock during the 90-day period following the effective date of the agreement, at prices determined in accordance with Rule 415(a)(4) under the Securities Act.”
Aquestive Therapeutics, Inc. entered into Warrant Issuance Agreement with funds managed by RTW (effective 2026-03-03).
“Concurrently, the Company entered into a Warrant Issuance Agreement with funds managed by RTW pursuant to which the Company agreed to issue a warrant to purchase up to 375,000 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $4.00 per share, expiring on March 3, 2029.”
Aquestive Therapeutics, Inc. amended Amendment No. 1 to Purchase and Sale Agreement with funds managed by RTW Investments, LP (effective 2026-03-03).
“On March 3, 2026, Aquestive Therapeutics, Inc. (the "Company") entered into Amendment No. 1 (the "Amendment") to the Purchase and Sale Agreement (the “Purchase and Sale Agreement”), dated August 13, 2025, with funds managed by RTW Investments, LP ("RTW").”
Santo J. Costa resigned as Director at Aquestive Therapeutics, Inc..
“On November 1, 2024, Santo J. Costa, a member of the Board of Directors of Aquestive Therapeutics, Inc. (the “Company”) and the Chairman of the Compensation Committee thereof (the “Compensation Committee”), notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective November 4, 2024.”
Aquestive Therapeutics, Inc.: Amended Article I, Section 11 of the Bylaws to shorten the look-back period for required information concerning stockholder nominations from three years to two years, and made technical and modernizing changes (e.g., replacing 'chairman' with 'chair') (effective 2024-10-16).
“On October 16, 2024, the Board of Directors (the “Board”) of Aquestive Therapeutics, Inc. (the “Company”), in connection with its periodic review of corporate governance matters, approved amendments, effective immediately, to the Company’s Amended and Restated Bylaws, as amended (the “Bylaws”). The Bylaws supersede the previously existing Amended and Restated Bylaws of the Company (the "Prior Bylaws"). Specifically, Article I, Section 11 of the Prior Bylaws, which sets forth requirements for stockholder nominations of candidates for election to the Board, has been amended to shorten the look-back period for required information concerning agreements, arrangements and understandings relating to stockholder nominations from three years to two years.”
Cassie Jung changed role as Chief Operating Officer at Aquestive Therapeutics, Inc..
“Aquestive Therapeutics, Inc. (the “Company”) has promoted Cassie Jung, 45, to Chief Operating Officer, effective June 3, 2024.”
Aquestive Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the first quarter ended March 31, 2024 and provided an update on recent developments in its business.”
Abigail L. Jenkins was appointed as Director at Aquestive Therapeutics, Inc..
“On April 1,2024, Aquestive Therapeutics, Inc. (the “Company”) announced the appointment of Abigail L. Jenkins to the Board of Directors of the Company (the “Board”), effective April 1, 2024.”
Aquestive Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Piper Sandler & Co. valued at $69.8 million net proceeds (effective 2024-03-19).
“On March 19, 2024, Aquestive Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") by and among the Company and Leerink Partners LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering of 16,666,667 shares of the Company's common stock, par value $0.001 per share ("Common Stock"), at a public offering price of $4.50 per share.”
Aquestive Therapeutics, Inc. updated its the third quarter ended September 30, 2023 guidance (raised).
“On November 6, 2023, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing its reported financial results for the third quarter ended September 30, 2023”
Aquestive Therapeutics, Inc. incurred senior notes of $45 million aggregate principal amount with purchasers named therein at 13.5% per annum maturing November 1, 2028.
“On November 1, 2023 (the “Closing Date”), Aquestive Therapeutics, Inc. (the “Company”) entered into purchase agreements (the “Purchase Agreements”) with the purchasers named therein (the “Purchasers”), in substantially identical forms, pursuant to which the Company agreed to issue and sell the $45 million aggregate principal amount of its 13.5% senior secured notes due 2028 (the “Notes”) to the Purchasers (the “Offering”).”
Aquestive Therapeutics, Inc. entered into Royalty Right Agreements with purchasers named therein valued at tiered royalty between 1.0% and 2.0% of annual worldwide net sales (effective 2023-11-01).
“the Company entered into royalty right agreements (the “Royalty Right Agreements”) with the purchasers named therein (the “Royalty Right Purchasers”), in substantially identical forms.”
Aquestive Therapeutics, Inc. entered into Collateral Agreement with Collateral Agent, the Trustee and the other grantors from time to time party thereto (effective 2023-11-01).
“the Company entered into a collateral agreement, dated as of the Closing Date, with the Collateral Agent, the Trustee and the other grantors from time to time party thereto (the “Collateral Agreement”).”
Aquestive Therapeutics, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $45 million aggregate principal amount of its 13.5% senior secured notes due 2028 (effective 2023-11-01).
“on the Closing Date, the Company entered into an indenture (the “Indenture”) governing the Notes with U.S. Bank Trust Company, National Association, a national banking association, as trustee (in such capacity, the “Trustee”) and collateral agent (in such capacity, the “Collateral Agent”).”
Aquestive Therapeutics, Inc. entered into Purchase Agreements with purchasers named therein valued at $45 million aggregate principal amount of its 13.5% senior secured notes due 2028 (effective 2023-11-01).
“On November 1, 2023 (the “Closing Date”), Aquestive Therapeutics, Inc. (the “Company”) entered into purchase agreements (the “Purchase Agreements”) with the purchasers named therein (the “Purchasers”), in substantially identical forms, pursuant to which the Company agreed to issue and sell the $45 million aggregate principal amount of its 13.5% senior secured notes due 2028 (the “Notes”) to the Purchasers (the “Offering”).”
Aquestive Therapeutics, Inc. entered into Letter Agreement valued at approximately $4,800,000.00 (effective 2023-08-01).
“On August 1, 2023, the Company entered into an Inducement Offer to Exercise Common Stock Purchase Warrants letter agreement (the “Letter Agreement”) with the holder (the “Exercising Holder”) of 5,000,000 of the remaining Common Stock Warrants (the “Existing Warrants”).”
Aquestive Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-21 meeting.
“The appointment of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2023 was ratified. Votes For Votes Against Votes Abstaining 40,091,281 438,344 203,299”
Aquestive Therapeutics, Inc. shareholders rejected Approval of an amendment to the Amended and Restated Certificate of Incorporation at the 2023-06-21 meeting.
“The proposal to approve an amendment to the Amended and Restated Certificate of Incorporation was not approved. Votes For Votes Against Votes Abstaining 22,312,401 3,252,699 1,021,036”
Aquestive Therapeutics, Inc. shareholders approved Approval of an amendment to the 2018 Equity Incentive Plan at the 2023-06-21 meeting.
“The proposal to approve an amendment to the 2018 Equity Incentive Plan was approved. Votes For Votes Against Votes Abstaining 18,972,308 7,272,348 343,991”
Aquestive Therapeutics, Inc. shareholders approved Election of Class II Director at the 2023-06-21 meeting.
“The following director nominee was elected to serve as Class II member of the Board of Directors, to serve for a three-year term until the Company’s 2026 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Nominee Votes For Votes Against Votes Abstaining Broker Non-Votes Gregory B. Brown, M.D. 24,757,783 — 1,830,864 14,144,277 John S. Cochran 24,886,102 — 1,702,545 14,144,277”
Aquestive Therapeutics, Inc. updated its first quarter ended March 31, 2023 guidance (raised).
“On May 2, 2023, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing its reported financial results for the first quarter ended March 31, 2023 and provided an update on recent developments in its business.”
Aquestive Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2022.
“Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the quarter and fiscal year ended December 31, 2022”
Aquestive Therapeutics, Inc. amended Amendment No. 11 with Indivior Inc. valued at $11,482,000 (effective 2023-03-02).
“Amendment No. 11 (the “Amendment”) to the Commercial Exploitation Agreement (the “Agreement’), dated as of August 15, 2008, with Indivior Inc.”
Aquestive Therapeutics, Inc.: Amended and restated Bylaws to update provisions on adjourned stockholder meetings, stockholder list inspection, and director nomination requirements, including compliance with Universal Proxy Rules (effective 2023-02-02).
“On February 2, 2023, the Board of Directors (the “Board”) of Aquestive Therapeutics, Inc. (the “Company”) amended and restated the Company’s Amended and Restated Bylaws, as amended (the “Bylaws”), effective immediately.”
Aquestive Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1)).
“December 30, 2022, Aquestive Therapeutics, Inc. (the “Company”) received a notice from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1), as the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has 180 calendar days, or until June 28, 2023, to regain compliance with the Minimum Bid”
Aquestive Therapeutics, Inc. updated its third quarter ended September 30, 2022 guidance (reaffirmed).
“On November 1, 2022, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the third quarter ended September 30, 2022 and provided an update on recent developments in its business.”
Aquestive Therapeutics, Inc. entered into Assertio License Agreement with Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc. valued at $9.0 million (effective 2022-10-26).
“Effective October 26, 2022, Aquestive Therapeutics, Inc. ("Aquestive" or the “Company”) entered into a License Agreement with Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc. (NASDAQ: ASRT) (“Assertio”), a specialty pharmaceutical company offering differentiated products to patients, to license Sympazan® (clobazam) oral film for the adjunctive treatment of seizures associated with Lennox‐Gastaut syndrome (LGS) in patients aged two years of age or older (the "Assertio License Agreement").”
Timothy E. Morris was appointed as Director at Aquestive Therapeutics, Inc..
“On August 10, 2022, the Company announced the appointment of Timothy E. Morris to the Company’s Board, effective August 5, 2022.”
Daniel Barber was appointed as Class I Director at Aquestive Therapeutics, Inc..
“In addition, the Board appointed Mr. Barber to fill the vacancy on the Board due to Mr. Kendall’s departure, to serve as a Class I Director with a term expiring at the Company’s 2022 Annual Meeting of Stockholders.”
Daniel Barber was appointed as President and Chief Executive Officer at Aquestive Therapeutics, Inc..
“Effective May 17, 2022, the Board appointed Daniel Barber, Senior Vice President and Chief Operating Officer of the Company, to the position of President and Chief Executive Officer of the Company.”
Keith J. Kendall departed as President and Chief Executive Officer at Aquestive Therapeutics, Inc..
“On May 17, 2022, Aquestive Therapeutics, Inc. (the “Company”) announced that Keith J. Kendall, President and Chief Executive Officer of the Company, is leaving the Company and Board of Directors (the “Board”) effective May 17, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.